Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) EBITDA (2016 - 2025)

Historic EBITDA for Cardiff Oncology (CRDF) over the last 15 years, with Q3 2025 value amounting to -$12.0 million.

  • Cardiff Oncology's EBITDA rose 497.58% to -$12.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$53.7 million, marking a year-over-year decrease of 1571.61%. This contributed to the annual value of -$48.7 million for FY2024, which is 713.25% down from last year.
  • According to the latest figures from Q3 2025, Cardiff Oncology's EBITDA is -$12.0 million, which was up 497.58% from -$14.8 million recorded in Q2 2025.
  • In the past 5 years, Cardiff Oncology's EBITDA registered a high of -$5.4 million during Q1 2021, and its lowest value of -$14.8 million during Q2 2025.
  • Over the past 5 years, Cardiff Oncology's median EBITDA value was -$10.9 million (recorded in 2024), while the average stood at -$10.7 million.
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 10349.14% in 2022, then surged by 928.48% in 2024.
  • Quarter analysis of 5 years shows Cardiff Oncology's EBITDA stood at -$9.5 million in 2021, then increased by 1.41% to -$9.4 million in 2022, then dropped by 10.01% to -$10.3 million in 2023, then decreased by 21.68% to -$12.6 million in 2024, then rose by 4.76% to -$12.0 million in 2025.
  • Its last three reported values are -$12.0 million in Q3 2025, -$14.8 million for Q2 2025, and -$14.4 million during Q1 2025.